Cellular immunotherapies for cancer

References

• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID: 20525992; https://doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30; PMID: 25399552; https://doi.org/10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID: 23724867; https://doi.org/10.1056/NEJMoa1302369
   PubMed Web of Science ®Google Scholar
• Bertrand F, Muller S, Roh KH, Laurent C, Dupre L, Valitutti S. An initial and rapid step of lytic granule secretion precedes microtubule organizing center polarization at the cytotoxic T lymphocyte/target cell synapse. Proc Natl Acad Sci USA 2013; 110:6073-8; PMID: 23536289; https://doi.org/10.1073/pnas.1218640110
   PubMed Web of Science ®Google Scholar
• Vasconcelos Z, Muller S, Guipouy D, Yu W, Christophe C, Gadat S, Valitutti S, Dupré L. Individual human cytotoxic T Lymphocytes exhibit intraclonal heterogeneity during sustained killing. Cell Rep 2015; 11:1474-85; PMID: 26027932; https://doi.org/10.1016/j.celrep.2015.05.002
   PubMed Web of Science ®Google Scholar
• Halle S, Keyser KA, Stahl FR, Busche A, Marquardt A, Zheng X, Galla M, Heissmeyer V, Heller K, Boelter J et al. In vivo killing capacity of cytotoxic T Cells is limited and involves dynamic interactions and T Cell cooperativity. Immunity 2016; 44:233-45; PMID: 26872694; https://doi.org/10.1016/j.immuni.2016.01.010
   PubMed Web of Science ®Google Scholar
• Petit AE, Demotte N, Scheid B, Wildmann C, Bigirimana R, Gordon-Alonso M, Carrasco J, Valitutti S, Godelaine D, van der Bruggen P. A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion. Nat Commun 2016; 7:12242; PMID: 27447355; https://doi.org/10.1038/ncomms12242
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3:e955691; PMID: 25941621; https://doi.org/10.4161/21624011.2014.955691
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, van de Rakt M, Lesterhuis WJ, van Riel M, Punt CJ et al. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res 2013; 19:1525-33; PMID: 23382117; https://doi.org/10.1158/1078-0432.CCR-12-1879
   PubMed Web of Science ®Google Scholar
• Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, Boerman OC, Croockewit S, Oyen WJ, van Rossum M et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013; 73:1063-75; PMID: 23345163; https://doi.org/10.1158/0008-5472.CAN-12-2583
   PubMed Web of Science ®Google Scholar
• Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res 2016; 22:2155-66; PMID: 26712687; https://doi.org/10.1158/1078-0432.CCR-15-2205
   PubMed Web of Science ®Google Scholar
• Bakdash G, Buschow SI, Gorris MA, Halilovic A, Hato SV, Skold AE, Schreibelt G, Sittig SP, Torensma R, Duiveman-de Boer T et al. Expansion of a BDCA1+CD14+ Myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines. Cancer Res 2016; 76:4332-46; PMID: 27325645; https://doi.org/10.1158/0008-5472.CAN-15-1695
   PubMed Web of Science ®Google Scholar
• Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247-60; PMID: 20479116; https://doi.org/10.1084/jem.20092140
   PubMed Web of Science ®Google Scholar
• Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014; 124:2246-59; PMID: 24667641; https://doi.org/10.1172/JCI73639
   PubMed Web of Science ®Google Scholar
• Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 2016; 22:433-8; PMID: 26901407; https://doi.org/10.1038/nm.4051
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319:1676-80; PMID: 3264384; https://doi.org/10.1056/NEJM198812223192527
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID: 18809613; https://doi.org/10.1200/JCO.2008.16.5449
   PubMed Web of Science ®Google Scholar
• Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö, Andersen MH et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res 2016; 22:3734-45; PMID: 27006492; https://doi.org/10.1158/1078-0432.CCR-15-1879
   PubMed Web of Science ®Google Scholar
• Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 2013; 19:4792-800; PMID: 23690483; https://doi.org/10.1158/1078-0432.CCR-13-0380
   PubMed Web of Science ®Google Scholar
• Donia M, Hansen M, Sendrup SL, Iversen TZ, Ellebaek E, Andersen MH, Straten Pt, Svane IM. Methods to improve adoptive T-cell therapy for melanoma: IFN-gamma enhances anticancer responses of cell products for infusion. J Invest Dermatol 2013; 133:545-52; PMID: 23014345; https://doi.org/10.1038/jid.2012.336
   PubMed Web of Science ®Google Scholar
• Idorn M, Thor Straten P, Svane IM, Met O. Transfection of tumor-infiltrating T Cells with mRNA encoding CXCR2. Methods Mol Biol 2016; 1428:261-76; PMID: 27236805; https://doi.org/10.1007/978-1-4939-3625-0_17
   PubMedGoogle Scholar
• Bonini C, Mondino A. Adoptive T-cell therapy for cancer: The era of engineered T cells. Eur J Immunol 2015; 45:2457-69; PMID: 26202766; https://doi.org/10.1002/eji.201545552
   PubMed Web of Science ®Google Scholar
• Hess Michelini R, Freschi M, Manzo T, Jachetti E, Degl'Innocenti E, Grioni M, Basso V, Bonini C, Simpson E, Mondino A et al. Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Cancer Res 2010; 70:3505-14; PMID: 20388780; https://doi.org/10.1158/0008-5472.CAN-09-4253
   PubMed Web of Science ®Google Scholar
• Hess Michelini R, Manzo T, Sturmheit T, Basso V, Rocchi M, Freschi M, Listopad J, Blankenstein T, Bellone M, Mondino A. Vaccine-instructed intratumoral IFN-gamma enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation. Cancer Res 2013; 73:4641-52; PMID: 23749644; https://doi.org/10.1158/0008-5472.CAN-12-3464
   PubMed Web of Science ®Google Scholar
• Manzo T, Sturmheit T, Basso V, Petrozziello E, Hess Michelini R, Riba M, Freschi M, Elia AR, Grioni M, Curnis F et al. T Cells redirected to a minor histocompatibility antigen instruct intratumoral TNFalpha expression and empower adoptive cell therapy for solid tumors. Cancer Res 2017; 77(3):658-671; PMID: 27872095; https://doi.org/10.1158/0008-5472.CAN-16-0725.
   PubMed Web of Science ®Google Scholar
• Manzo T, Sturmheit T, Basso V, Petrozziello E, Hess Michelini R, Riba M, Freschi M, Elia AR, Grioni M, Curnis F et al. T Cells redirected to a minor histocompatibility antigen instruct intratumoral TNFalpha expression and empower adoptive cell therapy for solid tumors. Cancer Res 2017; 77:658-71; PMID: 27872095; https://doi.org/10.1158/0008-5472.CAN-16-0725
   PubMed Web of Science ®Google Scholar
• Perez-Martinez A, de Prada Vicente I, Fernandez L, Gonzalez-Vicent M, Valentin J, Martin R, Maxwell H, Sevilla J, Vicario JL, Díaz MÁ. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp Hematol 2012; 40:882-91 e1; PMID:22771496; https://doi.org/10.1016/j.exphem.2012.07.004
   PubMed Web of Science ®Google Scholar
• Perez-Martinez A, Iyengar R, Gan K, Chotsampancharoen T, Rooney B, Holladay M, Ramírez M, Leung W. Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17:598-607; PMID: 20977942; https://doi.org/10.1016/j.bbmt.2010.10.019
   PubMed Web of Science ®Google Scholar
• Perez-Martinez A, Valentin J, Fernandez L, Hernandez-Jimenez E, Lopez-Collazo E, Zerbes P, Schwörer E, Nuñéz F, Martín IG, Sallis H et al. Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma in vitro and in vivo. Cytotherapy 2015; 17:601-12; PMID: 25541298; https://doi.org/10.1016/j.jcyt.2014.11.001
   PubMed Web of Science ®Google Scholar
• Nanbakhsh A, Pochon C, Mallavialle A, Amsellem S, Bourhis JH, Chouaib S. c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis. Blood 2014; 123:3585-95; PMID: 24677544; https://doi.org/10.1182/blood-2013-11-536219
   PubMed Web of Science ®Google Scholar
• Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res 2007; 31:1393-402; PMID: 17391757; https://doi.org/10.1016/j.leukres.2007.02.020
   PubMed Web of Science ®Google Scholar
• Fernandez L, Valentin J, Zalacain M, Leung W, Patino-Garcia A, Perez-Martinez A. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. Cancer Lett 2015; 368:54-63; PMID: 26276724; https://doi.org/10.1016/j.canlet.2015.07.042
   PubMed Web of Science ®Google Scholar